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The study of medications among pediatric patients has 
increased worldwide since 1997 in response to new legislation 
and regulations, but these studies have not yet adequately 
addressed the therapeutic needs of neonates. Additionally, 
extant guidance developed by regulatory agencies worldwide 
does not fully address the specificities of neonatal drug devel-
opment, especially among extremely premature newborns 
who currently survive. Consequently, an international consor-
tium from Canada, Europe, Japan, and the United States was 
organized by the Critical Path Institute to address the content 
of guidance. This group included neonatologists, neonatal 
nurses, parents, regulators, ethicists, clinical pharmacologists, 
specialists in pharmacokinetics, specialists in clinical trials and 
pediatricians working in the pharmaceutical industry. This 
group has developed a comprehensive, referenced White 
Paper to guide neonatal clinical trials of medicines – particu-
larly early phase studies. Key points include: the need to base 
product development on neonatal physiology and pharma-
cology while making the most of knowledge acquired in other 
settings; the central role of families in research; and the value 
of the whole neonatal team in the design, implementation 
and interpretation of studies. This White Paper should facilitate 
successful clinical trials of medicines in neonates by informing 
regulators, sponsors, and the neonatal community of existing 
good practice.
PURPOSE
This document is intended to assist investigators and spon-
sors of studies that evaluate medicinal products in neonates. 
Since terminology for drugs, medicines, and medicinal prod-
ucts varies around the world, we have simplified these distinc-
tions by using the term medicinal product throughout this 
document. While the focus of the document is on studies that 
will contribute to applications to regulatory authorities, the 
same principles apply to other studies involving neonates. In 
addition, this document may be useful for regulators who will 
be reviewing these studies. This document expands upon pre-
vious draft guidances entitled “General Clinical Pharmacology 
Considerations for Pediatric Studies for Drugs and Biological 
Products: Guidelines for Industry” from the US Food and Drug 
Administration (FDA) dated December 2014 (1), the European 
Medicines Agency’s (EMA) Guideline on the Investigation of 
Medicinal Products in the Term and Preterm Neonate (2), the 
International Conference on Harmonization’s (ICH) E11 (3), 
and the Tri-Council Policy Statement (4) and other related 
documents by Health Canada. Studies of pharmacodynamics 
effect, clinical efficacy, safety, and/or dose-finding in neonates 
involve gathering clinical pharmacology information, such 
as information regarding a product’s pharmacokinetics (PK) 
and pharmacodynamics (PD) that pertain to dose selection, 
optimization, and individualization. This document addresses 
general clinical pharmacology considerations for conducting 
studies in term and preterm neonates. That is, studies that 
generate information about dosing and preliminary safety for 
medicinal products evaluated in neonates. One goal of this 
document is to support the standardization and harmoniza-
tion of approaches to studies in neonates worldwide in order 
to facilitate global development of new and existing medicinal 
products for this vulnerable population.
The scope of this document is clinical pharmacology infor-
mation (e.g., PK, PD, and exposure-response (E-R) relation-
ships) that support findings of effect, efficacy, and safety and 
helps to identify appropriate dosages in term and preterm 
neonates. Since consideration of pharmaceutical quality and 
ethics influences many aspects of the design and implemen-
tation of clinical pharmacology studies, this document also 
discusses pharmaceutical quality, ethics, and participant wel-
fare during studies. This document also describes the use of 
quantitative approaches (i.e., pharmacometrics) to employ 
knowledge about disease and E-R from relevant prior clinical 
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studies to design and evaluate future studies in term and pre-
term neonates. The document does not describe (i) standards 
for regulatory approval of medicinal products in the neonatal 
population (ii) criteria to allow a determination that the course 
of a disease and the effects of a medicinal product on that dis-
ease are similar in adults and older pediatric populations.
While this document focuses on clinical pharmacology, it is 
important to remember that clinical pharmacology is embed-
ded in a broader medicinal product development strategy. For 
example, it may be necessary/possible to include assessments 
of efficacy in the same studies that assess dosage. Clinical phar-
macology studies may inform decisions by sponsors or regu-
lators about proceeding with development or be designed to 
reduce commercial and regulatory risk.
BACKGROUND
During the last two decades, recognition of the need for study 
of medicinal products in neonates has increased worldwide (5–
10). To address this need, a group of individuals with a broad 
range of expertise has been assembled to describe the issues 
that need to be addressed in the study of medicinal products 
in the neonate. This group includes regulators, neonatologists, 
developmental pharmacologists, parents, clinical trialists, 
pharmacometricians, and senior members of the pharmaceu-
tical industry with experience in the conduct of these studies. 
References are included to provide more in depth information 
than is possible in this document.
Worldwide efforts during the past two to three decades have 
increased the study of medicinal products in children, but 
not in the neonate. A review of the results of United States 
efforts illustrates the omission of neonates from these studies. 
Laughon et al. reviewed studies submitted to the FDA between 
1997 and 2010 in response to legislation to increase pediatric 
labeling (11). From a total of 428 medicinal products studied 
in pediatric patients, only 28 (7%) were studied in the neo-
nate. More importantly, the authors reviewed the actual use 
of those 28 medicinal products in the Newborn Intensive 
Care Unit (NICU) using a database comprised of 290 NICUs 
and 445,335 patients. Of the 28 medicinal products, 13 (46%) 
were never used in the NICU and 8 were used in <0.013% of 
patients. Even though 428 medicinal products were studied in 
pediatric patients, only 7 (1.6%) were actually used routinely 
in most NICUs. So, despite significant gains in understanding 
and improving medicinal product therapy for older children, 
neonates in the United States remain a population for whom 
therapy with off label medicinal products continues with min-
imal study (12). This off label use of medicinal products for 
neonates is a universal problem.
The reasons for the limited study of medicinal products in 
the neonate are complex. The immaturity, small size and rapid 
developmental changes in this high risk and vulnerable pedi-
atric population complicate the measurement of beneficial 
effects as well as adverse effects of medications. Increasing sur-
vival of neonates at 23 wk gestation (just over half of a full term 
40 wk gestation) requires evaluation of medical products in 
these extremely immature neonates, even if such studies were 
previously carried out in more mature neonates. Birth weights 
of neonates can range from <500–5,000 g and there are few 
validated endpoints to capture important effects of a variety of 
medications. Very large physiologic changes occur during this 
period of neonatal life, such as expression and maturation of 
enzymes, receptors, transporters, and neurotransmitters. Even 
the organs and tissues to be treated may respond differently or 
require different medicinal product concentrations to achieve 
comparable responses to those in older children or adults. 
Efforts to characterize maturation by age or size are still chal-
lenged by a broad range of biologic responsiveness that defies 
a simple description.
Additional features of the neonate make clinical trials chal-
lenging in this population. While some features of neonates are 
unique to this age group, others are simply more prominent 
than in other age groups. Many of these specific features are 
described in subsequent sections. The net effect of these speci-
ficities is that all neonatal medicinal product development 
programs are unique and require dedicated study designs to fit 
each individual medicinal product (13). Transposing a devel-
opment plan from other age groups is unlikely to be success-
ful. Neonatal medicinal product development plans require 
the integration of a number of perspectives including science, 
feasibility, welfare and ethics. This integration requires careful 
planning within study teams and across regulatory jurisdic-
tions. Neonatal medicinal product development benefits from 
careful choices made early in the development of a molecule 
because information needed for optimal development for neo-
nates may be captured best during preclinical and early phase 
clinical studies.
Definitions of the Neonate
Defining and classifying neonates is complex because differ-
ent terms are used to reflect maturations or clinical metrics 
such as birth weight. Postconceptional age (PCA) is difficult to 
determine, so postmenstrual age (PMA) has traditionally been 
more frequently used clinically, dating the gestation from the 
mother’s known or reported last menstrual period (14). When 
available, the best Obstetric Estimate (OE) of gestational age 
provides the best measure of gestation with a combination of 
the first day of last menstrual period, physical examination of 
the mother, prenatal ultrasonography, and history of assisted 
reproduction (15). Later ultrasound(s) and direct examination 
of the neonate are less accurate. Large discrepancies (>2 wk) 
in gestation between the OE and the neonate’s examination 
by an experienced clinician should rely upon the examina-
tion (14). The important issue about terminology is to be 
consistent within a study as well as between studies. Prior to 
the increased survival of premature neonates that began over 
40 y ago, the neonatal period was traditionally defined as the 
first 27 d after birth, which was followed by infancy (2). As 
neonatal survival at earlier stages of gestation increased, this 
convenient definition became increasingly inappropriate for 
a complete description of the neonatal population. A neonate 
born at 28 wk gestation would be classified as an infant when 
32 wk PMA was reached and was still quite immature in organ 
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development and responses. As has been adopted by the EMA, 
the optimal definition of a neonate is up to 44 completed weeks 
PMA. Infancy is from 44 completed weeks PMA to 1 y after 
the expected date of delivery (which is synonymous with 1 y 
corrected gestational age—corrected gestational age (CGA)—
usually considered the postnatal age (PNA) added to the weeks 
of gestation at the time of birth) (2).
Neonates have been grouped by birth weight (which is fea-
sible to obtain in all clinical settings) and by developmental age 
(which should be based on an assessment in early pregnancy 
and the neonate’s examination at birth). Term neonates are 
defined as 37–41 wk gestational age, (gestational age was used 
historically, but this is also postmenstrual age in newer termi-
nology), with more recent definitions further delineating early 
term (37–38 wk), full term (39–40 wk), and later term (41 wk), 
recognizing stratification of outcomes within term gestations 
(16). Post-term refers to ≥42 wk gestational age. Preterm neo-
nates are defined as any neonate born <37 completed weeks of 
gestation, (i.e., ≤36 wk + 6 d of gestation). A clinically-based 
classification for preterm neonates is as follows:
1. Moderate to late preterm infant: 32 to <37 wk gestational 
age
2. Very preterm infant: 28 to <32 wk gestational age
3. Extremely preterm infant: 24 to <28 wk gestational age
4. Preterm infants at the border of viability: 22 to <24 wk 
gestational age
Other definitions classify neonates by birth weight:
1. Low birth weight (LBW) infants: <2,500 g birth weight
2. Very low birth weight (VLBW) infants: <1,500 g birth 
weight
3. Extremely low birth weight infants (ELBW) infants: 
<1,000 g birth weight
4. Preterm infants at the border of viability: <600 g
Older age groups can be classified as follows:
•	 Neonates: birth up to 1 mo after expected date of  delivery 
(44 wk PMA)
•	 Infants: 1 mo after expected date of delivery up to 1 y
•	 Children: 1 y up to 12 y
•	 Adolescents: 12 y up to 16 y or 18 y in some jurisdictions 
(some jurisdictions would extend this period to 21 y of 
age).
Specific cutoffs for PNA are best developed using knowledge 
of the product under study and expected maturational changes 
of neonates in organ/tissue responsiveness and the disposition 
of the medicinal product.
Term and preterm neonates are a high-risk cohort of children 
because their physiology changes dramatically with both ges-
tational age (i.e., from 22–42 wk) and PNA. These changes can 
substantially affect medicinal product disposition and organ/
tissue responsiveness. The measurement or prediction of a 
medicinal product’s PK (exposure) and PD (response) is essen-
tial to the clinical pharmacology assessment. It is important to 
describe as fully as possible the E-R relationship of a medici-
nal product across the developmental gestational and postna-
tal spectrum for neonates that are expected to be treated with 
the medication. In addition, knowledge of pharmacogenetics, 
organ/tissue function/dysfunction, and concomitant medica-
tions, all of which can affect a product’s exposure and response, 
may also be required. Attention to the timing of the expression 
of pertinent proteins (e.g., transporters and receptors) should 
be considered when assessing the disposition and PD of a 
medicinal product in developmentally immature infants.
A further complexity is that growth abnormalities, either 
large for gestational age (LGA, weight >90th centile) or small 
for gestational age or growth restricted (SGA, weight <10th 
centile), can affect neonatal developmental physiology and 
pharmacology (17,18). Trials that exclusively use birth weight 
as an inclusion criterion generally include a larger proportion 
of growth-restricted, more mature neonates compared with 
those that use gestational age. Trials should specify whether 
or not neonates born outside the normal growth range will be 
included. The assessment of growth should be based on growth 
charts or standards such as standard deviation scores that have 
been validated for the population under study. This means 
that a given study may have to use different growth charts or 
standards in different locations and for different populations 
within a single study.
Some trials are conducted in health care settings that do not 
provide reliable dating of gestation in early pregnancy. Such 
trials rely on birth weight to classify neonates. The design and 
analysis of these trials need to consider that interindividual 
variation may reflect both development and growth. The num-
ber of days after birth (age) is referred to as PNA. The disposi-
tion of some medicinal products (and hence dosage regimen 
optimization) varies with PNA and/or with PMA. PNA needs 
to be accounted for in clinical studies.
During long-term follow-up it is important to account for 
expected developmental status. This can be done using CGA. 
During studies that are conducted over relatively short time 
periods (i.e., up to 3 mo after the expected date of delivery), it 
may be more convenient to refer to PMA than CGA.
Inclusion of specific age groups should reflect the aims of 
the study and may benefit from a narrow population to gen-
erate a clear signal of efficacy (or lack thereof). In contrast, 
detailed understanding of PK and PD will benefit by recruiting 
a broader population, since the thorough assessment of PK/
PD relationships hinges on the identification and quantifica-
tion of sources of variability. As more neonates born at 22 or 
23 wk gestation are treated in some centers, it will be impor-
tant to include such neonates in all relevant studies. The age-
stratifications cited here will help ensure that studies of clinical 
pharmacology sample all relevant stages of development. It 
should be noted that the results of clinical pharmacology stud-
ies may suggest that other age-stratifications for dosage are 
recommended in prescribing information (e.g., the label) or 
the summary of a medical product’s characteristics.
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CLINICAL PHARMACOLOGY CONSIDERATIONS
General Considerations
Several clinical pharmacology issues must be considered when 
designing and undertaking clinical trials in the neonatal popu-
lation. Neonatal studies require detailed planning that should 
start with a thorough assessment of existing knowledge. The 
team should then develop a clear concept of the treatment 
goal, identify knowledge gaps required to attain the treatment 
goal, design studies to fill the information gaps, conduct the 
studies and review the information continuously. When pos-
sible, information gaps should be filled from other sources, 
or at least the possibilities should be narrowed before clinical 
studies are conducted.
Early in the planning for a neonatal clinical trial, it is wise 
to involve neonatal nurses. They can provide valuable advice 
about the practicality of a study design and are pivotal in 
communication with families. Other relevant NICU caregiv-
ers, including respiratory therapists, social workers, pharma-
cists, and nutritionists, should be involved where appropriate. 
Another important aspect of planning clinical trials involves 
input from parents/guardians and children (potentially former 
preterm neonates) (19). They often provide valuable input not 
previously considered by investigators and their perspective 
on acceptable levels of risk may differ from that of investiga-
tors or even Ethics Committees (19–22). Efforts to include the 
perspective of NICU family advisory groups, parent support 
groups, and the individual family participants in the design 
and conduct of clinical trials should be strongly encouraged.
Neonatal specificities of the design of clinical trials arise 
because existing knowledge is likely to be incomplete and 
because studies will need designs that are specifically tai-
lored to this population to account for the practical, ethical 
and welfare features of research in this population. Modeling 
and simulation through pharmacometrics, physiologically-
based PK/PD modeling, as well as systems pharmacology 
modeling provide an ideal framework for knowledge syn-
thesis, study design (including trial simulation) and analysis. 
Pharmacometric methods can inform decisions about the 
number of participants, times of sample collection, covariates, 
phenotypic analyses, and population analyses. Physiologically-
based PKPD modeling provides a valuable knowledge synthe-
sis for the accurate prediction of results from first-in-human 
studies. Depending on the state of knowledge regarding etiol-
ogy and pathophysiology of a specific indication in the neo-
natal population, systems pharmacology can provide a useful 
(yet complex) platform to evaluate unexplored scenarios for 
future clinical trials. Given the incomplete knowledge about a 
medicinal product and ontogeny and the likelihood that data 
collection will be selective, study teams need to review their 
understanding of the data frequently. Models, assumptions, 
and study plans need to evolve as knowledge increases.
Traditionally, there is an expectation that each application 
for licensing/marketing authorization contains a self-sufficient 
body of data about the product ranging from preclinical data 
through a sequence of phases or exploratory/confirmatory 
studies. This approach is difficult to apply to neonates because 
of the issues identified in the Background. Instead, informa-
tion about a medicinal product may come from a number of 
sources. Preclinical animal models that are comparable to the 
conditions associated with preterm neonates must be cho-
sen carefully to correspond to the developmental stages of 
the organ to be studied (23–25). Some whole animal models 
do not survive long enough for adequate long-term neuro-
developmental assessment while others mature more rapidly 
than humans. Nonhuman primates have been used to study 
hypoxic-ischemic encephalopathy with findings that are simi-
lar to those seen in humans (26). Despite their small size, 
newborn mice have been used to study exposure to fluoroqui-
nolone antibiotics as well as potential musculoskeletal toxicity 
(27).
The timing of clinical studies in neonates should be appro-
priate to the condition and the medicinal product. The tradi-
tional approach has been to wait until phase III clinical trials 
have been completed in adults. This approach is not appropri-
ate in most situations. As outlined by Roth-Cline and Nelson, 
and as increasingly required by regulatory authorities, pedi-
atric medicinal product development should proceed as soon 
as “proof of concept” for the likelihood of direct benefit for 
neonates is established in adult studies, unless the disease is 
unique to newborns (28). The prospect of direct benefit to the 
neonate would depend on the disease and its severity, availabil-
ity of alternate treatments, and the absence of a major or sig-
nificant safety concern based on adult data or existing neonatal 
data when similar medicinal products or excipients have been 
previously studied. This can lead to concurrent development 
in pediatric patients, including neonates, and adults. Delay in 
the initiation of neonatal studies may unduly deprive them of a 
new and more beneficial therapy. It may also contribute to off-
label treatment without the guidance of evidence-based dos-
ing, safety, and efficacy data.
The identification of the appropriate ages to study and 
decisions on how to stratify data by age are medicinal prod-
uct-specific and require scientific justification, taking into con-
sideration developmental biology and pharmacology as well 
as the neonatal populations that are likely to be treated. Final 
dosing regimens and therapeutic recommendations may use 
different age strata from the strata used in trials.
Pharmacokinetics
In the neonate, size (e.g., body weight) and maturation (ges-
tational age at birth and PNA) are important determinants of 
medicinal product absorption, distribution, metabolism, and 
excretion (ADME) and explain a substantial amount of expo-
sure variability and changes in PK parameters. Maturation is 
usually accounted for by using surrogate markers such as GA, 
PMA, and PNA. In addition, other factors such as physiologic 
derangements (e.g., organ dysfunction and body cooling); 
concomitant or prior medication exposure; feeding status and 
type of feedings; and pharmacogenomics (among others) can 
influence ADME in term and preterm neonates. Therefore, the 
PK of a medicinal product is typically evaluated over a wide 
gestational age and PNA spectrum in which the agents will 
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be used (29–31). Areas that should be considered in planning 
neonatal PK studies are discussed in the following paragraphs. 
Not all of these areas are relevant to all medicinal products but 
they are listed so that investigators can make a comprehensive 
assessment of potential influences on dosing regimens.
Absorption. There are multiple developmental changes in neo-
nates that can affect absorption including:
1. effects on gastric acidity
2. rates of gastric and intestinal emptying
3. surface area of the absorption site




8. mode of administration (e.g., sublingual, through a 
nasogastric tube)
9. type of feeding (e.g., breast milk vs. formula)
10. cutaneous maturation
Similarly, developmental changes in skin, muscle, and fat, 
including changes in water content and degree of vascular-
ization can affect absorption patterns of medicinal products 
delivered by intramuscular, subcutaneous, or percutaneous 
routes (32).
Distribution. Distribution of a medicinal product can be 
affected by changes in body composition, such as changes in 
total body water and adipose tissue, which are not necessarily 
proportional to changes in total body weight. At birth, neo-
nates are born with a higher amount of total body water, which 
is mostly extracellular. The lower the gestational age of the neo-
nate, the higher the total body water (as a percentage of body 
weight) (33,34). After birth, term neonates generally lose up to 
10–15% of their total body water (higher for lower gestational 
age infants) in the first postnatal week, followed by a return to 
birth weight by 10–14 postnatal days (longer for lower gesta-
tional age infants). Plasma protein binding and tissue binding 
changes arising from changes in body composition with post-
natal growth and development may also influence distribution. 
Both the amount of protein and the nature of its binding may 
be reduced in preterm neonates (35). Differences in blood flow 
to an organ/tissue (e.g., brain and liver) between term and pre-
term neonates and older children and adults can also affect the 
distribution of a medicinal product in the body.
The implication of these findings is that clinical pharmacol-
ogy studies should control for these effects (which requires 
detailed collection of data informative about distribution, age, 
protein, and intercurrent illness) and whenever possible sam-
ples should be obtained with appropriate frequency in order to 
capture variation arising from changes in body composition.
Protein binding. Protein binding to a medicinal product or its 
metabolites may change with age and concomitant illness. An 
understanding of protein binding may be needed to interpret 
the data from a serum measurement and to determine appro-
priate dose adjustments (35–37). In term and preterm neo-
nates, protein concentrations are lower than in older children 
and adults, which can influence unbound medicinal product 
concentrations that dictate a pharmacologic effect as well as 
adverse effects at concentrations that are well tolerated by adults. 
In addition, nutrition is a major concern for the sickest neo-
nates and protein concentrations may remain low for weeks. In 
vitro plasma protein binding studies can determine the extent 
of binding of the parent and the major active metabolite(s) 
and identify specific binding proteins such as albumin and α-1 
acid glycoprotein. As demonstrated for bilirubin, competition 
for protein binding by different endogenous and exogenous 
chemicals may require careful evaluation of unbound medici-
nal product concentrations along with measurement of total 
circulating medicinal product concentrations. Albumin is the 
primary binding site for bilirubin with a 1: 1 molar ratio for 
the high affinity binding site (38–40). Based on its stoichiom-
etry, an albumin concentration of 2.5 mg/dl can bind ~20 mg/
dl of bilirubin in the absence of other chemicals that compete 
for these binding sites. Because of the risk of kernicterus, dis-
placement of bilirubin from its albumin binding site should 
be assessed as described by Robertson et al. if the medicinal 
product (e.g., ceftriaxone) is likely to bind to albumin and 
be administered to neonates (41,42). The implication is that 
studies need to account for protein binding, particularly if the 
product will be used in the weeks after birth when changes are 
most rapid and hyperbilirubinemia is common.
Metabolism. Medicinal product metabolism commonly 
occurs in the liver, but may also occur in many other organs, 
including the blood, gastrointestinal tract, kidney, lung, and 
skin. Developmental changes in metabolizing capacity can 
affect both bioavailability and elimination, depending on the 
degree to which intestinal and hepatic metabolic processes are 
involved (43). Although developmental changes are known, 
information on metabolism of specific medicinal products in 
neonates is limited. Each metabolic (or isoform) pathway, such 
as CYP enzymes, has unique ontogenic properties that need 
to be considered during study design because it will influence 
type and timing of study assessments (44).
A thorough review should be conducted of published studies 
of the most important metabolic developmental changes in the 
pathway for a specific medicinal product to potentially guide 
which developmental ages of neonates need to be targeted. In 
addition, some metabolizing enzymes (or their isoforms) may 
be present at birth in term and preterm neonates that are not 
present in older children and adults. Some of these isoforms 
may have similar or different affinity for substrates and activity 
relative to adult enzymes which needs to be considered dur-
ing medicinal product development. Both rates of metabolite 
formation and the principal metabolic pathway can be signifi-
cantly different in term and preterm neonates compared with 
adults and older children. The failure to appreciate differences 
in enzyme activity between age groups leads to inappropriate 
dosing regimens and safety problems in neonates (e.g., gray 
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baby syndrome with chloramphenicol). In vitro studies per-
formed early in medicinal product development may be useful 
in focusing attention on metabolic pathways that have already 
been studied in both adults and children. If specific informa-
tion about relevant pathways is not available, or if it is not 
known which pathways are relevant, then studies should allow 
for unanticipated variability.
Microdosing can be used to define metabolic pathways. 
Neonatal microdosing is feasible and acceptable to parents/
guardians, professionals and Ethics Committees (45–47) and 
may be helpful in some circumstances (e.g., complex meta-
bolic pathways that are different in neonates compared with 
adults or animal models) (46).
Excretion. The preterm neonate has an extremely low glomer-
ular filtration rate at birth, especially prior to 32–34 wk PMA 
(48,49). Postnatally, glomerular filtration rate increases rapidly, 
so PNA and gestational age can both affect the systemic expo-
sure of medicinal products when renal excretion is a dominant 
pathway of elimination. Studies should be designed to evalu-
ate those changes if renal excretion is an important pathway 
of elimination. The maturation of other excretory pathways, 
including biliary and pulmonary routes of excretion, is also 
important (50). Some medicinal products undergo active 
transport out of the liver, gastrointestinal tract, and brain 
which can prevent absorption (51,52). Others undergo active 
transport, especially into the liver and/or kidney depending on 
their chemical structures. The expression and maturation of 
transporters have not been thoroughly studied in developing 
humans. Additional developmental studies may be required 
to define the PK for medicinal products that are substrates 
for transporters. These data may need to be supplemented by 
basic science studies and organized to help define maturation 
of these pathways to assist with studies of medicinal products 
with similar pathways of elimination. Publication of stud-
ies for medicinal product approval can supplement basic sci-
ence studies and add to our understanding of developmental 
pharmacology.
Clearance of medicinal products as a function of age (ges-
tational and postnatal) is generally a valuable parameter 
for determining the dose for each age group in neonates. 
Medicinal product clearance has provided a valuable tool in 
the assessment of pediatric clinical pharmacology studies (53). 
Clearance may be widely variable depending on the gesta-
tional age of the infant and may change rapidly based on PNA. 
Clearance in target organs/tissues (e.g., brain) may also differ 
between neonates and older children/adults, so sampling com-
partments that are informative about target organs (e.g., cere-
brospinal fluid) is advised whenever feasible.
Variability. Growth and developmental changes in the term 
and preterm neonate create substantial changes in ADME, 
between individuals and within individuals. This leads to vari-
ability that may lead to substantial overdosing or underdosing 
or may require therapeutic drug monitoring. PK measure-
ments and parameters for a medicinal product may need to be 
described as a function of both gestational age and PNA and be 
related to body size and body weight (36,54,55). The matura-
tional changes in systems affecting ADME, such as membrane 
transporters and metabolizing enzymes should be taken into 
consideration in choosing appropriate gestational and PNA 
groups and doses to study. Developmental changes in PK 
parameters are quite variable among metabolic pathways and 
according to maturation measured by PMA or PNA. The rate 
of change in PK should be analyzed thoroughly to determine 
the best description of the rates of change that can be used to 
guide appropriate dosing after birth.
Analysis of PK by age (PMA and PNA). Changes in the rates 
of clearance can be analyzed relative to PMA at the time of 
study or relative to PNA because birth signals the onset of large 
changes in physiology, such as a cortisol surge and a change in 
cardiovascular hemodynamics. Data regarding the changes in 
PK related to Cytochrome P450 (CYP) 2C19, the major path-
way for clearance of pantoprazole, illustrate these differences 
(31). As can be seen in Supplementary Figure 1 online, clear-
ance did not change relative to PMA, but increased signifi-
cantly related to PNA.
These findings are consistent with what has been reported 
by Koukouritaki et al., using enzyme measurements from liver 
samples from a range of gestational ages showing low rates of 
CYP2C19 expression throughout gestation until birth when it 
starts to increase (Supplementary Figure 2 online) (56).
These data illustrate why the influence of birth on develop-
mental pharmacology should be included in the analysis of 
medicinal products in neonates.
Variations among different phase I enzymatic pathways 
should be expected and analyzed for individual medicinal prod-
ucts. This variation with age is illustrated in Supplementary 
Figure 3 online where CYP activity varies widely among 
individual phase I enzymatic pathways (56–59). Some reach 
maximum activity during the first few months after birth and 
then decrease as adults (60), while CYP2D6 steadily increases 
to maximum activity in adults (58). This developmental varia-
tion in the activity of specific CYP’s illustrates why pK for indi-
vidual drugs must be studied at the developmental ages when 
the drug is likely to be used in this developing population of 
neonates.
Physiologically based pharmacokinetics. When data are avail-
able to describe the developmental changes in pathways of 
medicinal product disposition, physiologically based PK 
(PBPK) may be a useful approach for integration of develop-
mental changes in specific processes that determine ADME. 
Study design can benefit from a better understanding of the 
components of PBPK such as changes with PMA and PNA 
in: maturation of phase I enzymes; maturation of conjugation 
pathways by phase II enzymes; changes in glomerular filtration 
rates; renal tubular and hepatic transporter expression and 
maturation; and transcutaneous medicinal product or excipi-
ent absorption. Unanticipated differences in medicinal prod-
uct clearance in neonates must be identified based on a careful 
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PK study. For example, the clearance of daptomycin as well as 
micafungin is faster in the neonate than in older infants and 
adults, thus requiring higher dosages (61,62). Although this is 
unusual in neonates, it emphasizes how inadequate PK studies 
could lead to under-dosing of these antibiotics in the neonate 
which could limit their efficacy.
Pharmacodynamics
Investigators should collect and analyze both PK and when-
ever possible PD data in neonatal studies to determine how 
the two are linked (i.e., the PK-PD or E-R relationship). PD 
may include the effect of the medicinal product on biomarkers 
or clinical endpoints for both safety and effectiveness as long 
as they are validated. These measurements may allow a bet-
ter understanding of whether the PK-PD relationships of the 
medicinal product in neonates are similar to those observed 
in older children or adults and may aid in deriving rational 
dosing strategies. Whenever possible, studies may assess E-R 
relationships to demonstrate the “effect” of a given medicinal 
product using direct measurements (i.e., physiologic param-
eters) or suitable biomarkers. It is important to determine 
whether the organ to be affected by the medicinal product in 
the neonate (e.g., heart) has the same capacity to respond as 
in older children or adults. Differences in capacity to respond 
can alter the E-R relationship significantly despite similar 
exposures. In some situations those questions may need to be 
studied through independent studies separate from the clinical 
trial. Interpretation of the E-R response in neonates is facili-
tated when there is an E-R response in other age groups. The 
ability to extrapolate may depend on a good E-R curve, which 
may be most efficiently obtained in the early phases of adult 
studies. This is one example of the importance of adequate 
planning for neonatal studies throughout the development of 
a medicinal product.
If the clinical endpoint cannot be measured directly because 
the effect is delayed or rare, then the selection of an appropri-
ate biomarker to substitute for the clinical efficacy or toxicity 
endpoint is essential.
Biomarkers. In general, the careful application and assessment 
of the right biomarker in the right populations is pivotal in 
medicinal product development. Biomarkers can support the 
diagnosis, prognosis, initiation of treatment, and the response 
to treatment. Biomarkers can be used in an individual neona-
tal medicinal product development program or qualified for 
a particular context of use across multiple medicinal product 
development programs (63,64).
A large number of neonatal biomarkers and clinically 
important outcomes have been described in several systematic 
reviews (65,66). Overall, biomarkers may have some utility in 
clinical practice, but insufficient high-quality data are available 
to support their use in neonatal medicinal product develop-
ment. In many cases, biomarkers are first evaluated in adult 
and/or non-neonatal pediatric population(s). The use of a 
biomarker in a neonate requires evidence to support a neo-
natal use. This is possible if the disease pathophysiology and 
pharmacologic response in pediatric patients are sufficiently 
similar to adults. Sufficient similarities are not always present, 
as exemplified by low blood pressure. For instance, low blood 
pressure is a useful biomarker in adults for systemic under-
perfusion and shock, while it has not been a useful biomarker 
in neonates for evaluation of organ perfusion. In neonates, 
clinically meaningful surrogate outcomes or biochemical 
biomarkers borrowed from older age groups or therapeutic 
contexts may not reflect biological events (the combination 
of disease and ontogeny) with sufficient precision to predict 
a lasting effect for a medicinal product. If sufficient evidence 
to support the use of a biomarker in neonates is not available, 
then the medicinal product development program should 
include work to develop evidence that supports the use of that 
biomarker in neonates.
The pathophysiology of many neonatal conditions fre-
quently involves multiple organ systems, so analysis of a single 
biomarker may not be sufficient. Despite these limitations, 
biomarkers can have utility in medicinal product development 
(e.g., population enrichment strategies). Biomarkers that are 
specific for age, organ, and condition may be more useful as 
PD biomarkers. Novel techniques and biomarkers (metabolo-
mics, genomics, microRNA, etc.) offer great potential, but will 
also require a detailed and structured development program to 
establish validity.
Short and long term outcomes. When selecting outcomes, it 
is important to note that neonates may be uniquely suscep-
tible to medicinal products that cross the blood brain barrier 
and to other physiologic changes that may impact neurologic 
development (e.g., hypoxemia and/or acidosis). In addition, 
the immaturity of organ systems in neonates mean that safety 
signals may manifest a considerable time after the product is 
administered. It is necessary to include the assessment of safety 
in the study objectives and it is usually necessary to follow neo-
nates beyond the period of safety surveillance of 30–90 d that 
is typically used in adults. Neonates may need to be followed 
up to 2 y CGA or older (when speech and language can be 
assessed). While longer-term surveillance of safety and effi-
cacy may help define more accurate endpoints, surrogate out-
comes such as reduced length of hospital stay, the incidence 
of comorbidities, biomarkers, and health care costs should be 
important factors in neonatal medicinal product development. 
This would remain true even if longer-term outcomes cannot 
consistently demonstrate benefits between experimental treat-
ment and placebo groups. There are a number of issues to con-
sider when selecting long-term outcomes and deciding how 
they best fit into a neonatal medicinal product development 
program.
Long-term outcome studies currently pose major challenges 
due to problems with patient dropout and relocation, quality 
control, diagnostic accuracy, interpretation of the measures 
themselves, underlying medical conditions, and potential 
environmental effects postdischarge. Parental socioeconomic 
status and education must be measured in the assessment of 
developmental outcomes.
698 Pediatric RESEARCh     Volume 81 | Number 5 | May 2017
Official journal of the International Pediatric Research Foundation, Inc.
Study of drugs in the neonate         Special Article
Short-term outcomes do not always correlate with long-
term outcomes. This discordance may arise because other 
determinants of health are dominant in the years after ini-
tial hospital discharge (e.g., social and environmental fac-
tors such as maternal education and socioeconomic status) 
or because short-term outcomes are not sensitive to harm or 
benefit.
It may be necessary to move away from a global scale of 
neurodevelopment or composite outcomes (including mortal-
ity) to scales where researchers can focus on those measures 
that might be the most important for the particular interven-
tion being evaluated. It may be possible to use global scales as 
markers of safety rather than efficacy.
There is a definite need to examine the effects of gender, 
ethnicity, race, social status, environmental influences, etc. in 
clinical studies since these factors can also impact short and 
more importantly long-term outcomes.
There is a significant need for investigators, regulators, gov-
ernment, funding agencies, and industry to develop and then 
accept a standardized and specific set of short- and long-term 
endpoints for a variety of medical conditions and disease 
phenotypes in neonates (with proper validation of long-term 
assessment tools, especially with respect to neurodevelopmen-
tal outcome as well as other organ functions).
Long-term outcomes studies may be best conducted as part 
of a postmarketing risk management plan rather than as part 
of the initial dossier that leads to the availability of the prod-
uct on the market. For some disorders it may be appropri-
ate to conduct studies up to the expected date of delivery in 
the approval studies and to include subsequent follow-up for 
safety and efficacy in a postmarketing risk management plan. 
For some disorders (e.g., bronchopulmonary dysplasia), lon-
ger periods of follow-up are needed to accurately evaluate the 
effects on morbidity and even mortality.
Pharmacogenetics
Genetic differences that clinically affect both exposure and 
response have been increasingly documented, but the rela-
tionship between genomic profiles and developmentally reg-
ulated gene expression has not been extensively studied in 
neonates. Some of the difficulties in obtaining specific phar-
macogenetic information in pediatric patients, including 
neonates have been reviewed (43). Nevertheless, if medicinal 
product exposure in a neonatal clinical pharmacology study 
is dependent on a well-known pharmacogenetic biomarker 
(e.g., CYP2D6) (67), obtaining DNA may provide additional 
information for the interpretation of the PK and PD results. 
In particular, if there are important pharmacogenetic differ-
ences affecting PK, efficacy and safety of a medicinal prod-
uct in the adult population, pharmacogenetic analysis of 
the target genes is recommended in neonates, given that the 
relationship between phenotype and genotype may be com-
pletely different in the neonate compared with other patient 
groups (68,69). DNA collection may be performed on scav-
enged blood samples after PK analyses are performed or on 
buccal swabs.
POINTS TO CONSIDER FOR NEONATAL CLINICAL TRIALS
A sponsor who will be submitting an application for a medici-
nal product that includes a new active ingredient, indication, 
dosage, dosing regimen, or route of administration must sub-
mit an initial pediatric study or investigation plan (70). This 
pediatric plan should outline the neonatal study or studies that 
the applicant plans to conduct unless a waiver is granted. The 
submission of the initial neonatal plan is intended to encourage 
sponsors and investigators to consider neonatal studies early 
in product development and begin planning for these studies 
when appropriate. The initial plan must include the following: 
(i) an outline of the neonatal study or studies that the applicant 
plans to conduct (including, to the extent practicable, study 
objectives and design, age groups, relevant endpoints, and sta-
tistical approach); (ii) any request for a deferral, partial waiver, 
or waiver if applicable, along with any supporting information; 
and (iii) other information specified in an individual country’s 
regulations.
When designing neonatal clinical studies, investigators and 
sponsors should be mindful that modeling and simulation as 
well as developmental pharmacologic considerations are often 
critical for the successful completion of a study. Modeling and 
simulation using all of the available information should be an 
integral part of all neonatal development programs. The use of 
modeling and simulation is still developing and lessons from 
individual studies should be shared in order to facilitate the 
development of the field.
The neonatal plan is a living document and it is expected 
that the plan will evolve with time. The plan is useful for direct-
ing the process for the sponsor as well as meeting a regulatory 
requirement. Early and frequent discussion of the neonatal 
plan between sponsors and regulators is extremely valuable 
and highly recommended. Investigators and networks can add 
considerable value at all stages of the development and imple-
mentation of a plan.
Approaches to Neonatal Studies
Clinical pharmacology studies assess PK (i.e., medicinal prod-
uct exposure), PD (i.e., effect on biomarker or clinical end-
point), and E-R relationships. It is essential to study these 
topics in neonates because neonates may differ from adults. 
In addition, a medicinal product development program that 
includes neonates should consider the specific end-organ/tis-
sue responsiveness, metabolic enzyme(s), excretory systems, 
and transporters that may also be specific to neonates. This is 
best achieved by characterizing the PK of the medicinal prod-
uct and the responses across the appropriate gestational and 
PNA ranges of neonates who are likely to be treated with the 
medicinal product. Adequate numbers of neonates across age-
strata should be enrolled to provide accurate guidance for dos-
ages for the developmental ages of patients who are likely to be 
treated with the medication. It is not unusual to make incor-
rect estimates of key parameters such as clearance. For this 
reason it is important to include early assessments of clearance 
after 5 or 10 patients are studied in each neonatal age group. 
An early assessment of clearance is particularly important if 
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the data will be used for the purpose of extrapolation of indi-
cations/uses because an extrapolation approach will generate a 
relatively small set of data. If an inaccurate initial estimate of 
clearance is not identified early in the study then conclusions 
of the study may be erroneous.
Extrapolation
Extrapolation is a well-recognized approach to providing suf-
ficient evidence to support the safe and effective use of medici-
nal products in pediatric populations. As described by Dunne 
and associates (71) and the EMA CHMP (72) extrapolation 
of efficacy findings from studies in older populations can be 
successful. This means that a development program can be 
devised for neonates that minimizes the burden of the research 
on the participants and allows development of medicinal prod-
ucts for rare conditions. Note that minimizing the burden on 
the neonates does not make the development program “easier” 
for the Sponsor.
The principles of extrapolation are common across jurisdic-
tions but the terminology can differ. Accordingly it is impor-
tant to seek a globally integrated approach to extrapolation. 
The primary rationale for extrapolation is to avoid unneces-
sary studies in the target population for ethical reasons, for 
efficiency, and to allocate resources to areas where studies are 
the most needed. Many diseases in the preterm and term new-
born infant are unique or have unique manifestations preclud-
ing extrapolation of efficacy from older pediatric patients and 
call for novel methods of outcome assessment. Alternatively, in 
situations where the feasibility of studies is restricted, extrapo-
lation principles may be applied for rational interpretation of 
the limited evidence in the target population in the context of 
data from other sources (28).
The prerequisite for extrapolation is a well-justified case 
that reasonable similarity can be assumed between source 
and target population of both disease progression and 
response to intervention. As noted above, data from other 
age-groups and other conditions can inform the design of a 
development program based on extrapolation. It is impor-
tant to use extant data systematically although regula-
tory agencies have different ways to structure the case for 
extrapolation.
The EMA Concept Paper suggests that a staged approach 
is used to develop a framework for reduction of the required 
evidence should extrapolation be justified. The stages are: 
examine clinical context in order to justify why extrapolation 
may be appropriate instead of a complete set of prospective 
studies; develop an extrapolation concept based on biological 
and pharmacological rationale with quantitative predictions 
on the degree of similarity in the target population (model-
ing and simulation can help quantify available information); 
develop an extrapolation plan by proposing a reduced set 
of supportive studies in the target population in accordance 
with the extrapolation concept. In general, data generated in 
the target population should validate the extrapolation con-
cept and complement those data that may be extrapolated 
from the source population. Studies should focus on those 
complementary areas, e.g., age subsets, where the largest dif-
ferences to the source population are expected.
The extrapolation concept should be validated using data 
obtained from studies included in the extrapolation plan; draw 
conclusions about extrapolation while taking account of risks 
and uncertainties (28). If the data do not confirm the extrapola-
tion concept, the concept needs to be updated by the emerging 
data regarding the true extent of similarity and, hence ability to 
extrapolate. Consequently, the need to generate more data in 
the target population should be assessed and the extrapolation 
plan adjusted.
The FDA has published a decision tree that leads to the selec-
tion of an approach to extrapolation (71,73). In any case, if a 
study will be used to seek regulatory approval the assumptions 
will have to be clearly demonstrated, quantitatively, if possible. 
The approaches suggested by FDA, which may also be accept-
able to the EMA are:
If Extrapolation of E-R is possible: Study Dose-Exposure. This 
approach is appropriate when it is reasonable to assume that 
neonates, when compared with adults or older children, have 
(i) a similar progression of disease; (ii) a similar response of 
the disease to treatment; (iii) a similar E-R or concentration-
response relationship; and(iv) the medicinal product (or active 
metabolite) concentration is measureable and predictive of the 
clinical response. Support for concluding that there is a simi-
lar disease course and medicinal product effect in adult and 
pediatric populations (including term and preterm neonates) 
includes evidence of common pathophysiology and natural 
history of the disease in the adult and pediatric populations, 
similar concentration-response relationships in each popu-
lation, and experience with the medicinal product, or other 
medicinal products in its therapeutic class, in the disease or 
condition or related diseases or conditions. This approach 
generally involves E-R knowledge from studies in adults. An 
example of this approach is fluconazole for the prevention and/
or treatment of invasive candidiasis (74–76).
The condition is similar but extrapolation of exposure response 
is not possible although E-R is well characterized in other age 
groups: Study Dose-E-R (including studies of PD and efficacy). 
If the disease and intervention are believed to behave similarly 
in neonates and adults, but the E-R in term and preterm neo-
nates is either inadequately defined or thought not to be suf-
ficiently similar, a reduced set of studies in the neonates could 
be sufficient to demonstrate efficacy To use this approach, the 
E-R relationship in adults and older children should be well-
characterized. The goal of such an approach is to characterize 
and compare the E-R relationship in adults and in the term 
and preterm neonatal population with the appropriate term 
and preterm neonatal doses based on the E-R relationships 
seen in term and preterm infant patients. Although clinical 
measures (e.g., symptoms, signs, and outcomes) can be used 
to select doses, an appropriate biomarker that can be consid-
ered to be related to such an endpoint should also be studied, 
if available. If there is uncertainty about whether extrapolation 
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of efficacy is appropriate, an adequately powered study using a 
clinical endpoint may be necessary to provide an answer to the 
scientific question of interest. An example of this approach is 
the use of meropenem for the treatment of complicated intra-
abdominal infections (77,78).
No extrapolation of E-R is possible: Develop a full neonatal 
program. If the disease progression is unique to neonates or 
its progression and/or response to intervention is undefined or 
dissimilar to that in adults or older children, then the neonatal 
plan should provide substantial evidence of the safety and effi-
cacy of the medicinal product in one or more clinical studies, 
usually evaluating more than one dose. The study objectives 
are to provide evidence of safety and efficacy and to character-
ize the PK and E-R relationships to aid in optimizing neonatal 
dosing strategies. A population PK analysis can be conducted 
concurrently using PK data from the efficacy study to confirm 
PK estimates in the gestational age and PNA subgroups. If pos-
sible and appropriate, PD endpoints should also be collected 
in such studies to increase knowledge on the disease and the 
pharmacological target and to ensure sound dose finding/
selection. An example of a disease limited to term and preterm 
neonates would be respiratory distress syndrome (79–81).
When response data is collected (efficacy or PD) it should 
be used to validate and confirm the initial assumptions related 
to pharmacology, disease history and clinical response to the 
new compound. Response or PD data may include biomark-
ers or clinical endpoints for both safety and effectiveness. The 
specific endpoints for an E-R evaluation for each medicinal 
product should be discussed with regulators (preferably in a 
globally coordinated manner). A dedicated PK study is nearly 
always required for neonates regardless of the approach taken 
if the investigational medicinal product is likely to be used in 
this population. Safety data must always be collected.
Sampling Procedures
Conventional PK studies with intensive blood sampling are 
rarely performed in neonates because of the limited circulat-
ing blood volume (82). There is a lack of consensus on per-
missible blood volumes and there is limited information about 
the tolerability of blood sampling in neonates (83). Parents are 
unlikely to consent if the sampling is perceived to be burden-
some. Conducting PK sampling during times of routine labo-
ratory sampling (opportunistic sampling) is an approach that 
reduces the number of blood draws for PK sampling only. This 
approach can yield similar PK models to study-specific sam-
ples taken at optimized time points (84). In any case the total 
amount of blood taken during a study must be meticulously 
recorded including blood removed for the study but not used 
in analysis (e.g., while flushing dead spaces). Cerebrospinal 
fluid may also be collected for PK sampling during times of 
routine clinical laboratory evaluations. Scavenged sampling, 
by using blood or other fluid leftover in the laboratory after 
clinical studies have been completed, is another noninvasive 
approach as is the use of residual dried blood spots. Chemical 
stability of the medicinal product in the storage conditions of 
the laboratory should be confirmed. Careful consideration to 
the timing of dose, time of collecting the samples (to optimize 
the value of the information to the PK model and fit with clini-
cal and laboratory routines) and the integrity of the samples is 
important for these approaches. Urine and saliva may be col-
lected noninvasively, but the interpretation of medicinal prod-
uct analyses can be challenging. The use of salivary diagnostics 
and genomics has grown in importance and accuracy in corre-
lating with blood levels of various proteins and genes (85,86). 
Within the next several years, saliva may be used routinely for 
PK or other laboratory studies if issues relating to transport 
into saliva and binding proteins can be resolved.
Neonatal Dose Selection for Clinical Pharmacology Studies
This section presents some general principles, acknowledging 
that experts in this field must be included in the study team. 
Since there may be limited information on the safety of the 
dose of medicinal product to be administered, the dose range 
in first-in-age group studies requires careful consideration. 
In general, the potential risk of the treatment must be com-
mensurate with the prospect of direct benefit to the patient or 
without the prospect of direct benefit, but likely to yield gen-
eralizable knowledge about the patient’s disorder (87). Factors 
for consideration include (i) similarity of the disease and E-R 
in adults or older children; (ii) for enteral preparations, the 
relative bioavailability and potential differences with types of 
feeds; (iii) the gestational age, PNA, and developmental stage 
of the population; (iv) any recognized pharmacogenetic influ-
ences on disposition of the medicinal product; (v) the toxicity 
of the medicinal product; and (vi) PK data from other pedi-
atric populations. Initial doses are nearly always normalized 
to body size (mg/kg) or some other form of scaling, based on 
appropriate justification. When uncertainty about the dose is 
high, cautious approaches will often be appropriate, including 
initial titration of an intentional low dose or use of therapeutic 
drug monitoring during the trial.
When extrapolation of efficacy is considered, so that only PK 
studies are conducted, the PK studies in the neonate should 
determine how to achieve the same level of systemic expo-
sure in adults or older children. This requires that the neona-
tal organ responsiveness is similar to that of adults or older 
children. Dosing, safety, and/or efficacy may be affected by 
gestational age and PNA because neonates often have wide dif-
ferences in interpatient variability in PK measures and param-
eters. In these instances, the sponsor should specify the criteria 
by which exposure matching would be acceptable. For exam-
ple, one approach would be to use simulations to select the 
appropriate dosing strategy to estimate the appropriate range 
of exposures (e.g., 5th to 95th percentile) shown to be safe and 
effective in adults or older children.
As science and technology continue to advance, in silico and 
other alternative modeling methods may be developed that 
can provide preliminary data to inform the design and conduct 
of PK/PD studies for investigational medicinal products in 
neonates. For example, the development of a physiologically-
based PK (PBPK) in silico model that integrates medicinal 
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product-dependent parameters (e.g., renal clearance and 
metabolic pathways) and system-dependent parameters (e.g., 
nonmedicinal product parameters such as blood flow, protein 
binding, and enzyme and transporter activities) is one possible 
approach. PBPK has been used in pediatric medicinal product 
development programs for (i) planning for a first-in-pediatric 
PK study, (ii) optimizing the study design, (iii) verifying the 
model in specific gestational and/or PNA groups, (iv) recom-
mending starting doses, (v) informing enzyme ontogeny using 
a benchmark medicinal product, and (vi) facilitating covariate 
analysis for the effects of organ dysfunction or medicinal prod-
uct interactions in pediatric patients (88). The model selected 
should incorporate in vivo PK/PD data obtained in adults and 
older children as well as human volunteer studies, as appropri-
ate. It is important to evaluate the reliability of the (PBPK/pop-
PK/PD) model and its predictions with regards to the prior 
knowledge and to check the validity of major assumptions.
Clinical trial simulations can be performed to integrate PK, 
PD, disease progression, and study design considerations to 
help guide a neonatal medicinal product development pro-
gram. In neonates, due to constraints related to enrollment 
and blood sampling, clinical trial simulations can be particu-
larly helpful to assess sample size considerations and design a 
trial that’s both feasible and can adequately evaluate medici-
nal product exposure, safety, and effectiveness. An estimate of 
the E-R relationship across a range of body-size doses (dose/
kg) may be important. For the “Dose-Exposure-Response” 
approaches discussed above, investigation of a range of doses 
and exposures should allow assessment of those relationships, 
development of rational dosing instructions and validation/
confirmation of the initial assumptions.
Where PK/PD studies are designed, the dose range should 
account for observed differences in response between older 
children and adults with the neonatal population, both in 
terms of exposure and response (89). For example, there is 
evidence that pediatric populations are on average less sen-
sitive to antihypertensive medicinal products than the adult 
population. Therefore, neonatal studies may include exposures 
greater than the highest medicinal product exposure associ-
ated with the approved adult dose, provided that prior data 
about the E-R relationship and safety information justify such 
an exposure. Studies of distinctly different ranges of exposure 
are desirable to provide sufficient information for the calcula-
tion of an optimal dose.
Neonatal Dosage Forms and Formulations
There are challenges associated with any route of administra-
tion in neonates, as recently summarized by Linakis et al., and 
the EMA Committee for Medicinal Products for Human Use 
(2,90). Formulations that permit accurate dosing and enhance 
adherence or accuracy in dosing (i.e., dose accuracy without 
manipulation) in neonates are a crucial part of clinical phar-
macology studies and subsequent pharmacotherapy. If there 
is a neonatal indication, an age-appropriate dosage formula-
tion must be made available on the market (91). The route of 
administration mainly depends on the characteristics of the 
compound. Although oral or intravenous administration is 
most common, other routes (e.g., inhalational, intraocular, 
transcutaneous, intramuscular, subcutaneous or rectal) can be 
considered when appropriate. Some stages of product develop-
ment can be done using a product that is not ideal followed 
by bridging studies when the commercially available prepara-
tion becomes available. The appropriateness of bridging results 
from bioavailability studies in adults to children should be jus-
tified, as there could be rare examples of differences in sensitiv-
ity toward formulations.
One way to fulfill this requirement is to develop and validate 
a neonatal formulation, and seek approval for that formulation 
with respect to the available guidance on how to evaluate such 
a formulation. Besides concentration and dose flexibility that 
should result in a reasonable volume to insure accuracy of dos-
ing, excipients are of specific relevance and importance in neo-
nates (92). Excipients with known toxicity in neonates should 
be avoided (e.g., ethanol, propylene glycol or benzyl alcohol 
(93,94)), if possible. There has recently been a concerted effort 
between different stakeholders to build a dataset to cluster the 
available knowledge—including safety information—on excip-
ients in neonates (95). This has been organized in the Safety 
and Toxicity of Excipients for Pediatrics (STEP) database at 
http://www.eupfi.org/step-database/ for which anyone can 
register (96). It is possible to measure excipients in microsam-
ples and to perform population PK studies in neonates (97,98). 
It is important to consider exposure to excipients as well as to 
active ingredients; that is to assess the circulating concentra-
tion-time profile rather than rely on quantitative information 
about the excipient content of the product. Studies of prod-
uct use in neonates have shown that many products thought 
to require excipients can be made without excipients (99). It 
is possible to use clinical trials to gather data about excipients 
and there are opportunities for precompetitive collaboration 
about excipient safety. It can be useful to compare exposures 
to excipients associated with new products to those in existing 
products known to be safe, however careful attention should 
be put on relevance of age, dose, route of administration and 
disease. Concern about excipients is not a valid reason to defer 
or avoid the development of a medicinal product for neonates.
If the sponsor demonstrates that all reasonable attempts to 
develop a stable, specific and safe formulation have failed, the 
sponsor should develop and validate an age-appropriate for-
mulation that can be prepared by a pharmacist in a licensed 
pharmacy using an approved medicinal product and commer-
cially available ingredients. If the sponsor conducts the neona-
tal studies using such a formulation, the following information 
should be provided in the study report:
•	 A statement on how the selected final concentration was 
optimized to help ensure that the doses can be accurately 
measured with commercially available dosing devices;
•	 A statement that the volume to be prepared is appro-
priate to be dispensed for a course of therapy for one 
neonate, unless there are safety factors that necessitate 
decreasing the volume to be prepared;
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•	 A listing of all excipients, including diluents, suspend-
ing and stabilizing agents, sweeteners and flavoring and 
coloring agents (quality and quantity);
•	 Information on containers (designated containers should 
be readily and commercially available to retail pharma-
cies) and storage requirements (if possible the most user 
friendly storage condition (room temperature) should 
be evaluated and or studied);
•	 Testing results on formulation stability, not to exceed 
the expiration date of the original medicinal product lot 
from which the pediatric formulation is derived.
The bioavailability of any formulation used in neonatal stud-
ies should be characterized in relation to the adult formulation. 
If needed, a relative bioavailability study comparing the age-
appropriate formulation to the approved medicinal product 
should be conducted in adults. Potential medicinal product-
food (including milk) or vehicle interactions should be con-
sidered, such as those that have been reported with apple juice 
(100). In addition, preterm infants <34 wk rarely feed orally, 
and are most often fed through a nasogastric or orogastric tube, 
sometimes using an infusion pump. The influences of mixing the 
product with feeds and rate of administration should be taken 
into consideration. Binding to the plastic in the most frequently 
used feeding tubes should be tested. Extended-release dosage 
forms or combination products produced for adults should be 
made available for neonates as an age-appropriate formulation 
when it is appropriate to do so (although prolonged clearance 
means that there is less need for extended release formulations 
in the neonatal population). Such formulations should not be 
limited to drops or liquids, since more novel approaches like 
uncoated minitablets have been reported (101).
Finally, intravenous administration has specific issues (e.g., 
dead space, flow rate, flush volume, and medicinal product 
volume) as recently summarized by Sherwin et al. (102). The 
general guidelines on formulation development of intravenous 
administration apply, with some aspects that are more specific 
for neonates. Study medicinal products should be adminis-
tered separately from other medicinal products if possible. If 
the medicinal product is administered as a prolonged, continu-
ous infusion then coadministration with other products will 
be necessary when the product is used in clinical practice, due 
to limited vascular access. Prior to coadministration, compat-
ibility of the medicinal product with total parenteral nutrition 
and other relevant intravenous medicinal products needs to be 
examined. Other aspects of the dosage form should be justi-
fied including the intravenous volume (single dose and daily 
dose) to be administered. Data on the range of potential final 
strengths (concentration) may be clinically important because 
it influences the volume administered and dose flexibility. Issues 
related to electrolyte and excipient exposure, as well as choice 
and flexibility in diluents, should also be explored and reported.
Study Design including Sample Size
For clinical investigators working to improve the treatment of 
neonatal diseases with low incidence rates (e.g., rare diseases), 
traditional sample size requirements for clinical research may 
impede the conduct of the trial. Regulatory guidance on tri-
als in small populations advises that alternative approaches to 
conducting such trials might be suitable if they can improve 
the interpretability of trial results. Innovative trial designs that 
have been used in rare disease populations may be applicable 
to neonates. Algorithms for application of innovative trial 
designs to neonates have not yet been developed. However, 
integrating aspects of innovative trial designs into more ‘‘stan-
dard’’ approaches may include adaptive designs, defined as ‘‘a 
study that includes a prospectively planned opportunity for 
modification of one or more specified aspects of the study 
design and hypotheses. This should be based on analysis of 
data (usually interim data) from subjects in the study (103).
Examples of such study modifications could include: (i) 
changes in power calculations leading to enrollment modifi-
cation and early termination criteria stemming from a futility 
analysis; (ii)use of pragmatic trials which include patients in 
routine clinical practice settings, typically incorporating com-
parative effectiveness research comparing the safety and effec-
tiveness of diagnostic, therapeutic, or delivery system options; 
(iii) incorporation of additional nontrial neonatal data from 
electronic health records and other auditable sources on 
medicinal product dose and response; and (iv) incorporation 
of prior information through Bayesian techniques may make 
adaptive designs even more practical and powerful.
Number of Patients. The precision of PK and E-R parameters 
in the sample size calculation are critical for neonatal studies. 
Prior knowledge of the disease, exposure, and response from 
adult and other relevant pediatric data, such as that related 
to variability, can be used to derive sample size for ensuring 
precise parameter estimation. The sponsor should account 
for potential sources of variability, including intersubject and 
intrasubject variability, and differences between adults and 
older children in the final selection of the sample size for each 
age group.
The sponsor should discuss and justify the distribution of the 
number of participants across each age range and the appro-
priateness of the ranges with regulators, because this will be 
medicinal product-specific. For example, one approach would 
be to prospectively target a 95% confidence interval within 
60% and 140% of the geometric mean estimates of clearance 
and volume of distribution for the medicinal product in each 
subgroup with at least 80% power. In general, noncompart-
mental modeling with rich sampling has not been used in 
neonates. Instead, population PK modeling analysis based 
on sparse PK sampling, or other scientifically justified meth-
ods can be applied to achieve this precision standard (104). 
Conceivably, certain disease states might not allow for recruit-
ment of an adequate number of participants to meet the stan-
dard, but practical considerations should be taken into account 
in determining the sample size.
Number of Samples per Patient. The number of blood sam-
ples collected in a clinical pharmacology study, to estimate 
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PK measures and parameters for each patient in the study 
should be carefully considered. The number of samples is often 
very limited in neonates (for more on collection of blood or 
plasma samples, see section below). Using times of routine 
blood draws (e.g., clinically indicated laboratory testing) for 
opportunistic sampling can reduce the number of blood draws 
for research purposes only. Clinical trial simulations or opti-
mal sampling techniques may be recommended to justify the 
proposed sampling scheme. Blood volume limitations for PK 
sampling will vary by gestational and PNA and this can affect 
the number of PK samples for medicinal products requiring 
>0.5 ml of whole blood per sample. Newer microsampling 
techniques can provide measurements of multiple analytes 
(e.g., electrolytes, blood glucose, and blood gases) on a single 
0.3 ml sample of blood. Accelerator mass spectrometry can use 
samples as small as 7 µl. Additional sampling for medicinal 
product or metabolite concentrations is also recommended 
when an adverse event occurs.
Sample Collection. Blood or plasma concentrations of medici-
nal product or metabolites have been used as supporting 
evidence of effect or dose selection through E-R analyses in 
children. However, the volume and frequency of blood sam-
pling are often of concern in neonatal studies (105). Blood 
samples can be obtained by direct venipuncture or through 
the use of an indwelling intravascular catheter, especially with 
the need for repeated samples. Heel sticks, commonly used 
in this population, can also be used to collect blood samples. 
Unless there are data that indicate a difference between arte-
rial, venous, and capillary blood concentrations, all sources 
of blood should be allowed. In order to validate the micro-
analytic approaches in neonatal PK studies, this approach 
needs to be incorporated into adult development programs 
by inclusion of capillary samples when possible. The volume 
and frequency of blood sampling can be minimized by using 
microvolume medicinal product assays, dried blood spots, 
sparse-sampling techniques, and population PK approaches. 
These types of assays and analyses are especially relevant when 
studying neonates (106). Modern assay techniques allow small 
sample volumes to be used to determine medicinal product 
concentration, but data quality may be affected if the sample 
volume is insufficient to allow for reanalysis when necessary 
(107). Blood samples for analysis should be collected from the 
circulating blood volume and not from reservoir dead space 
created by catheters or other devices. Sampling technique is 
critical when using available neonatal indwelling intravenous 
catheters. The time of sample collection, proper sample trans-
portation and storage, and sample handling techniques should 
be documented. Whenever possible, PK samples should be 
collected from a separate site from the one used to adminis-
ter the medicinal product. The collection of fluids including 
blood, cerebral spinal fluid, or bronchial fluids for medicinal 
product concentration measurements may be beneficial when 
samples are being obtained for clinical purposes. Noninvasive 
sampling procedures, such as urine and saliva collection, may 
be adequate if correlated with outcomes or if the correlation 
with blood or plasma levels has been documented.
Given the difficulty in collecting blood samples in neonates, 
special approaches to allow optimal times of sample collection 
may be useful (108–110). Sampling windows may need to be 
wider than is typical for an adult study to account for diffi-
culty in sampling. The sampling scheme should be planned 
carefully to obtain the maximum information using the mini-
mum number of samples. If possible, additional PK samples 
should be collected when adverse events occur in order to bet-
ter understand the relationship between medicinal product 
exposure and potential toxicity. Samples for DNA should be 
collected when appropriate, as discussed previously.
Participant welfare is of paramount importance during 
clinical trials. Trial planning needs to account for the avail-
ability of experienced staff, techniques for analgesia (e.g., 
topical anesthetics, pacifiers or oral sucrose) and applicabil-
ity across different units. During the first week or two after 
birth, sick neonates may have umbilical catheters, which may 
be an optimal site for blood sampling. The small caliber of 
other vascular access devices in neonates may limit direct 
sampling (e.g., venous cannulae or long lines). Neonates are 
susceptible to infections so multiple samples from surgically-
placed (Broviac/Hickman) or other central lines may need to 
be limited (111). The pros and cons of sampling routes have 
been summarized (112).
Covariates and Phenotype Data. The sponsor should obtain, 
at a minimum, the following covariates for each neonate: ges-
tational age at birth, birth weight and head circumference, 
PNA, current weight, race, ethnicity, sex, diagnoses, concomi-
tant and recent medications or intravenous fluids (including 
blood transfusions), and relevant laboratory tests that reflect 
the function of the organs responsible for medicinal product 
elimination. Occasionally the weight that dosing is based on 
may differ from the actual weight (e.g., treatment of neonatal 
abstinence syndrome with opioids). Investigators are encour-
aged to collect DNA samples in neonatal PK studies under the 
circumstances described above, along with appropriate pheno-
typic information to optimize the interpretation of pharma-
cogenetic influences on PK and PD parameters. For example, 
when genetic information is obtained for a cytochrome P450 
enzyme, the sponsor should examine the influence of genetic 
mutations on PK, PD, and/or dose-response to determine 
whether genetically defined subsets of patients may need spe-
cial dosing considerations (113).
The sponsor should examine the relationship between the 
covariates and the PK of the medicinal product of interest. The 
contribution of size (e.g., body weight), maturation (e.g., ges-
tational age at birth, PNA, PMA), and other covariates to PK 
variability should be assessed. If factors affecting the PK of the 
medicinal product are to be studied (e.g., the effect of a con-
comitant medication or the presence or absence of a disease), 
a justification for the numbers of patients with and without 
those factors in the study should be included.
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Sample Analysis. An accurate, precise, sensitive, chemically-
specific, and reproducible analytical method to quantify the 
medicinal product and metabolites in the biologic fluids of 
interest is essential. A method that is readily adaptable and that 
uses only minimum sample volumes should be chosen.
Data Analysis
Two basic approaches for performing the PK analysis in neo-
nates can be used; a noncompartmental PK approach and a 
population PK approach.
Noncompartmental Analysis. The noncompartmental analysis 
PK approach involves administering either single or multiple 
doses of a medicinal product to a relatively small group of 
patients with relatively frequent blood and urine sample collec-
tion. Samples are collected over specified time intervals chosen 
on the basis of absorption and disposition half-lives (predicted 
from other studies with modification based on known matura-
tion of the route(s) of disposition), and subsequently assayed 
for either total or unbound concentrations of medicinal prod-
uct and relevant metabolites. Noncompartmental analysis 
can be used to establish PK parameters such as area under 
the curve (AUC), maximum (peak) concentration (Cmax), 
clearance (CL), volume of distribution, and half-life which 
are descriptive of the concentration of medicinal product or 
metabolite(s) over time. Data are usually expressed as the 
means of the relevant measure or parameter and interindivid-
ual variances. This approach should include a sufficient num-
ber of neonates to give a precise estimate of the mean: standard 
approaches can be applied to neonates. If medicinal product 
administration and sampling are repeated in a PK study, some 
understanding of intraindividual variability in PK parameters 
can be obtained. A noncompartmental approach is often not 
feasible in neonates.
Population Analysis. An alternative approach for analysis 
in pediatric clinical pharmacology studies is the popula-
tion approach to PK analysis. Population PK accommodates 
infrequent (sparse), but informative, sampling of blood 
or plasma from a larger patient population than would be 
used in a compartmental or noncompartmental analysis PK 
approach to determine PK parameters. Sparse sampling of 
blood or plasma is considered more acceptable for neonatal 
studies, because the total volume of blood sampled can be 
minimized. Sampling can often be performed concurrently 
with clinically necessary blood or urine sampling. Because 
relatively large numbers of patients are studied and samples 
can be collected at various times of the day and repeated 
over time in a given patient, estimates of both population 
and individual means, as well as estimates of intra and inter-
subject variability, can be obtained if the population PK 
study is properly designed.
E-R analyses predominantly employ a population analysis 
approach. Individual analysis is generally not recommended 
unless responses from a wide range of doses from each neo-
nate are available. Simultaneous modeling of data across all 
enrolled neonates provides the best opportunity to describe 
the E-R relationship.
Adverse and Serious Adverse Event Reporting
It is crucial to capture safety data in all neonatal clinical phar-
macology studies. This need is particularly acute in neonates 
because of the limited number of participants in clinical stud-
ies—particularly if an extrapolation approach is used. Safety 
must be included in the objectives of all studies of medicinal 
products in neonates. Maturing organs may be damaged in the 
neonatal period, but that damage may only become manifest 
as the child develops. It is often difficult to distinguish whether 
morbidity and mortality observed in a critically ill neonate is 
from a possible effect of the medicinal product being studied 
or the underlying clinical condition (especially in neonates at 
the limits of viability). Neonatal pharmacovigilance has been 
described (114). Du et al. have outlined and tested a method 
for evaluation of the relation of an adverse event to the admin-
istration of a medication (115). They developed a classification 
of the relation to the medicinal product as definite, probable, 
possible or unlikely based on the following 13 criteria:
1. Timing of the event relative to the administration of the 
medication
2. Whether the event was a well-documented complication 
of the medication
3. Whether there are published reports of the event related 
to the suspected medicinal product in neonates
4. Whether the event was a change in a pre-existing 
condition
5. Whether alternative explanations might explain the 
event
6. Whether any alternative explanations are able to be 
confirmed
7. Whether the event improved after the medicinal product 
was discontinued
8. Whether a reduction in dosage reduced the severity of 
the event
9. Whether the event improved after administration of a 
specific antagonist
10. Whether the event improved or disappeared while the 
patient continued to receive the suspected medication
11. Whether the event reappeared or worsened when the 
suspected medication was reintroduced
12. Whether the suspected medication was detected in 
blood or other body fluids in toxic concentrations
13. Whether there was unequivocal evidence that the dose 
was an overdose
Adverse events represent any change in a condition or 
appearance of a new problem that was not present before the 
beginning of the study medication. Such changes in condi-
tion are quite common in all premature neonates who are not 
involved in a study making it difficult to distinguish medicinal 
product-related changes and potential interactions between 
medicinal products. A placebo treated group can be quite 
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important in separating out the effects of a study medication 
from changes related to the underlying condition (e.g., pre-
maturity). Appropriate reporting of serious adverse events 
and adverse events to designated Institutional Review Boards, 
Data Safety Monitoring Committees, and Regulatory Agencies 
should occur based on regulations in each country where the 
research is being conducted. It is worth noting that in some 
countries, serious adverse events that are anticipated as part of 
neonatal intensive care and are thought to be unrelated to the 
study medicinal products or procedures may be reported over 
the same timelines as nonserious adverse events.
ETHICAL CONSIDERATIONS
During the last 50 y, medical treatment of sick neonates has 
progressed from antibiotics to mechanical ventilation to pro-
longed artificial heart-lung support with extracorporeal mem-
brane oxygenators. Numerous medicinal products accompany 
these medically complex treatments, but most are prescribed 
off-label or not licensed for the treatment of neonates (11,116). 
Even the few that are labeled for the neonate are unlikely to 
have received adequate study to support prescribing for the 
extremely premature neonate. Treatment of neonates with 
medical products without the benefit of comparable evidence 
provided for adults through appropriate clinical trials is usu-
ally unethical (117,118).
Not only do clinical trials in neonates present special medi-
cal and pharmacologic challenges that have been outlined 
above, they also present ethical challenges (119). Neonates 
are a vulnerable population for a variety of reasons such as 
the inability to comprehend the risks of a study, to express 
their views about those risks or to choose whether or not to 
participate (28,120). As noted at several points in this docu-
ment, there are significant uncertainties about the effects of 
medicinal products, the optimal dose and the long-term con-
sequences of administering medicinal products to neonates. 
These factors make a benefit-risk balance more difficult than 
in other settings. Sick neonates face significant burdens during 
routine care. The additional burdens of participation in clini-
cal research need careful justification. Nevertheless it is more 
important to protect neonates from poor or missing medicinal 
products by conducting well-planned and justified research 
than it is to protect neonates from research.
In order to provide adequate protection for children in clini-
cal trials, many countries have developed guidelines about 
how the studies should be conducted (3,6,22,105,121–123). As 
clinical trials have become international in scope, it is essen-
tial to adhere to the pediatric policies within each country and 
those of the responsible Ethics Committees while adapting to 
the needs of neonates. However, variations among nations and 
among local Institutional Review Board’s (IRB’s) within coun-
tries in the interpretation and implementation of guidelines 
for studies in neonates can present challenges to any interna-
tional clinical trial.
Certain ethical principles that are found in most interna-
tional regulations related to clinical trials apply to neonates 
(22). International guidelines such as ICH E6 state that “before 
a trial is initiated, foreseeable risks and inconveniences should 
be weighed against the anticipated benefit for the individual 
trial subject and society. A trial should be initiated and con-
tinued only if the anticipated benefits justify the risks” (22). 
In general, most, if not all investigators, regulators, regulations 
and ethicists recognize that neonates are a vulnerable popu-
lation that should only be exposed to low risk interventions. 
Some national guidelines manage the process of weighing risks 
against benefits of a trial by classifying the risks, for example as 
minimal risk (4,124). Some countries recognize a category of 
trials that represent a minor increase over minimal risk (125). 
The use of risk categories adds to the complexity of assessing 
risk because the interpretation of which interventions are low or 
minimal risk varies between countries and Ethics Committees. 
Some Ethics Committees would classify a blood draw as mini-
mal risk while others regard this as a minor increase over mini-
mal risk (126). For studies classified as a minor increase over 
minimal risk that provide the prospect of direct benefit for the 
subject, the ceiling on risk is determined by whether it is pro-
portional to the probability and magnitude of benefit (127). 
According to most regulatory guidelines, a clinical trial with-
out the prospect of direct benefit to the individual neonate is 
possible with appropriate parental consent, but only if the trial 
will provide generalizable knowledge about the underlying 
condition being studied (87). Parents/guardians, children and 
neonatal care providers can provide important advice about 
acceptable levels of risk relative to the potential benefits and 
should be included early in the planning process for all clini-
cal trials involving children, especially neonates (14,22–24). 
If available data do not indicate whether a specific treatment 
is beneficial for neonates, then participation in a study about 
the treatment is deemed to provide a prospect of direct benefit 
for those infants receiving the investigational product. When 
a placebo arm is involved, risk to those infants must be low 
(128). In any case, therapeutic trials are usually conducted in 
neonates with a condition or disorder for which the medicinal 
product is indicated. It is essential to recognize that neonates 
face significant risks because of exposure to medicinal prod-
ucts that have not been adequately evaluated (129,130). Once 
new, improved medicinal products reach the market, they will 
be used in neonates even if they have not been studied ade-
quately in this population. Furthermore, sick neonates are rou-
tinely exposed to a number of interventions as part of routine 
clinical care, many of which are painful (131). In this context, 
the risks and potential harms arising from research studies 
may not add substantively to the burdens borne by neonates. 
The risks, burdens and benefits of each research study should 
be identified. For each study the recognition of acceptable risks 
and burdens should be based on an explicit balance with the 
benefits of research in a way that takes into account the views 
of families.
Before initiation of a clinical trial, a duly appointed, inde-
pendent Ethics Committee must approve the proposed trial. 
The Ethics Committee must have access to sufficient exper-
tise in neonatal research. Given the limited number of rel-
evant experts and the need for consistent decision-making 
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arrangements, federated Ethics Committees or a single Ethics 
Committee for each country will work particularly well for 
neonatal clinical trials (similar to current models for cancer 
trials) as long as it includes appropriate expertise.
An Independent Data, Safety and Monitoring Board (sepa-
rate from the local Ethics Committee) may be needed to over-
see the trial (122,132). This committee should be comprised 
of Pediatricians and/or Neonatologists, Biostatisticians, com-
munity members, and other appropriate personnel with suf-
ficient expertise to be able to examine the safety and efficacy of 
the trial and stop a trial if there are significant concerns about 
safety or if it becomes apparent (through interim analyses) that 
the medicinal product is not efficacious.
Permission for the participation of a neonate in a clini-
cal trial can be challenging. This permission must be free of 
undue influence and coercion, although the parents or legally 
appointed guardian(s) of a sick neonate are likely to be in a 
state of heightened anxiety. This heightened anxiety may make 
the possibility of benefit from a therapeutic intervention seem 
particularly attractive or the uncertainty about therapeutic 
options and outcomes in a randomized trial particularly stress-
ful. The person obtaining parental permission must remain 
neutral and maintain equipoise about whether either arm of 
the study is better or worse. Parents must be provided ample 
time to consider the study and to formulate questions about 
their child’s participation. The definition of ample time will 
depend on the context of the study. Families may visit sick neo-
nates irregularly and consent procedures need to account for 
this. When it is appropriate for the study design, the process 
of continuous consent allows families to extend the decision-
making process (133).
Ethical considerations may be interpreted differently in 
different jurisdictions. Sponsors and investigators need to be 
mindful of the variation in ethical approaches while aiming to 
develop a consistent global approach and avoid locating studies 
in outside countries where the regulatory agencies will be most 
flexible and provide limited oversight. This will be become 
increasingly complex with an increased number of clinical tri-
als in neonates being conducted in multiple countries simulta-
neously, requiring standardizing and harmonizing clinical and 
ethical approaches globally. Despite the ethical challenges of 
conducting clinical trials in neonates, they do deserve the ben-
efit of drug therapy grounded in thorough studies conducted 
in patients with similar degrees of immaturity.
CONCLUSIONS
Neonatal clinical pharmacology studies are unique. There is 
an ethical imperative to minimize the number of participants 
in neonatal clinical studies and a need to study new and exist-
ing medicinal products as efficiently as possible. These driv-
ers promote an approach to clinical pharmacology that starts 
with a broad search for existing knowledge and uses phar-
macometric tools to integrate existing knowledge in order to 
plan and analyze clinical studies. The interpretation of new 
and existing knowledge is an iterative process with multiple 
review steps.
It is important to plan neonatal studies early in the medicinal 
product development process. Important data to support the 
application of a medicinal product to neonates may need to be 
gathered during the adult phases of clinical medicinal product 
development. Preclinical studies may need to include juvenile 
animal studies.
Multiple stakeholders must work well together to insure the 
successful development and regulation of neonatal medicinal 
products, and the International Neonatal Consortium (INC) 
was established to help promote that collaborative process. 
Establishing and maintaining relationships among the key 
stakeholders of a neonatal development plan need special 
attention. Teams including regulators need to be open-minded 
about study design and focused on filling information gaps 
using the most appropriate approach. Sponsors and investiga-
tors need to develop better ways to share information relevant 
to all neonatal studies in a precompetitive way. For example, 
pooling adverse event rates in the placebo arms of neonatal 
trials will inform all clinical development programs by iden-
tifying the rates of anticipated adverse events in neonates who 
have not been exposed to novel treatments. Information about 
how surrogate outcomes relate to clinically important out-
comes will improve the design of clinical programs by allowing 
the refinement of surrogate outcome measures. It is essential 
that both positive and negative trials be published so that all 
relevant information concerning the outcomes of a trial is 
available.
Many neonatal conditions have a major public health impact 
but involve rare diseases and have relatively few patients. This 
means that a global development pathway is needed for most 
medicinal products used in neonates. While sponsors need to 
work closely with multiple regulatory agencies and investiga-
tors, regulators need to develop processes to reach agreement 
as often as possible during the development and implementa-
tion of neonatal programs to develop medicinal products.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at 
http://www.nature.com/pr
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